CASE REPORT article
Front. Oncol.
Sec. Skin Cancer
Volume 15 - 2025 | doi: 10.3389/fonc.2025.1647603
Talimogene Laherparepvec Treatment for Mucosal Melanoma with Metastatic Lymph Node Metastasis: Case Report
Provisionally accepted
- University of Vermont The Robert Larner MD College of Medicine, Burlington, United States
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Mucosal melanoma is a rare and aggressive subtype of melanoma, accounting for approximately 1% of all melanoma cases. Of those, only 4% occur primarily in the vagina. Talimogene Laherparepvec (T-VEC) is a biopharmaceutical medication that is used to treat unresectable malignant melanoma. However, the clinical trials for this treatment option excluded patients with mucosal melanomas. Here we report a case of an 85-year-old female with vaginal melanoma with regional lymph node metastasis that had complete durable response to combined T-VEC and immune checkpoint inhibition treatment. This is, to our best knowledge, the first reported case of T-VEC treatment for vaginal melanoma. It supports findings from case reports demonstrating good response to T-VEC in mucosal melanomas of the urethra, maxillary sinus, and the soft and hard palate. Prospective studies assessing the efficacy of T-VEC in treating mucosal melanoma are needed to confirm these findings.
Keywords: Mucosal melanoma, malignant melanoma, T-VEC, Immunotherapy, Lymphatic Metastasis
Received: 16 Jun 2025; Accepted: 30 Sep 2025.
Copyright: © 2025 Ingason, Muruganandam, Chidobem, Cintolo-Gonzalez and Rehman. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Arnar B Ingason, arnar144@gmail.com
Hibba Rehman, hibba.rehman@uvmhealth.org
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.